Vote On $7 Billion Ensco/Pride Deal Set For End Of May

Shareholders of offshore drilling contractors Ensco and Pride International will vote on May 31 on the proposed acquisition of Pride by Ensco for more than $7 billion.

The deal, struck in early February, is set to create the world's second-largest rig fleet, and the combined company would challenge Seadrill for the number-two ranking by market capitalization.

The two companies also disclosed new names for 23 of Pride's 26 rigs. The three shallow-water rigs not renamed - Pride Pennsylvania, Pride Hawaii and Pride Wisconsin - are not currently being marketed and were all built in the 1970s.

Ensco Chief Executive Dan Rabun, noting that Ensco had sold four of its own shallow-water jackup rigs last year, said last week there would be opportunities to dispose of some non-core assets after the acquisition, but gave no further details.

Rivals including Transocean and Noble Corp are taking hard looks at their fleets in order to improve their overall quality and age profile.
An Ensco spokesman was not immediately available for comment on Tuesday.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.